Latest Market News

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Westgold Resources is set to demerge its non-core Reedy and Comet gold projects into a new ASX-listed entity, Valiant Gold, aiming to unlock value and fast-track cash flow through a strategic ore purchase agreement.

Fortuna Metals has confirmed a significant rutile discovery at its Mkanda project in Malawi, with high-grade drill results reaching up to 2.21% rutile over wide intervals. This discovery, adjacent to a world-class deposit, signals strong potential for a large-scale titanium feedstock resource.

Biotron Limited’s BITO securities have been suspended from ASX trading due to non-compliance with key listing rules, raising questions about the company’s next steps.

Mt Malcolm Mines has executed a binding agreement to acquire key components of a 500,000 tonnes per annum gold processing plant, positioning itself for future self-processing and toll-milling opportunities in the prolific Leonora gold region.

EV Resources is set to begin a fully funded maiden diamond drilling program at its high-grade Los Lirios antimony project in Mexico, aiming to define a maiden JORC resource by Q3 2026. This marks a pivotal step toward production readiness and a broader 2026 exploration campaign.

Nova Minerals Limited has voluntarily suspended trading of its shares on the ASX pending a capital raising announcement expected on 17 December 2025.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Fortifai Limited introduces Nol8, a breakthrough platform that processes data in real time with millisecond latency, promising to transform industries reliant on massive data flows.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.